Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-24T04:25:59.210Z Has data issue: false hasContentIssue false
  • English
  • Français

Time to evaluate long-acting neuroleptics?

Published online by Cambridge University Press:  09 July 2009

David C. Watt
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Information
Psychological Medicine , Volume 5 , Issue 3 , August 1975 , pp. 222 - 226
Copyright
Copyright © Cambridge University Press 1975

References

Allan, R. N., and White, H. C. (1972). Side effects of parenteral long-acting phenothiazines. British Medical Journal, 1, 221.CrossRefGoogle ScholarPubMed
Andrews, W. N. (1973). Long-acting tranquillisers and the amotivational syndrome in the treatment of schizophrenia. In Community Management of the Schizophrenic in Chemical Remission, pp. 1–4. Edited by King, M. H.. Excerpta Medica: Amsterdam.Google Scholar
Ayd, F. J. Jr, (ed.) (1973a). The Future of Pharmacotherapy. New Drug Delivery Systems. International Drug Therapy Newsletter: Baltimore, Md.Google Scholar
Ayd, F. J. Jr, (1973b). Side effects of depot fluphenazines. In The Future of Pharmacotherapy. New Drug Delivery Systems, pp. 69–76. International Drug Therapy Newsletter: Baltimore, Md.Google Scholar
Ayd, F. J. Jr, (1974). Side effects of depot fluphenazines. Comparative Psychiatry, 15, 277–284.CrossRefGoogle ScholarPubMed
Blackwell, B. (1973). Drug deviation in psychiatric patients. In The Future of Pharmacotherapy. New Drug Delivery Systems, pp. 17–31. Edited by Ayd, F. J. Jr.. International Drug Therapy Newsletter: Baltimore, Md.Google Scholar
Blake, B. (1969). The Use of Long-Acting Phenothiazines in a Rural Area. Symposium on Long-acting Phenothiazines, Dublin, 15–26. E. & R. Squibb (U.K.).Google Scholar
British Medical Journal (1964). Leading article: Side-effects of phenothiazine drugs, 2, 1412.Google Scholar
Byrne, L., O'Connor, T., and Fahy, T. J. (1974). The home behaviour of schizophrenic patients living in the community and attending a day centre. British Journal of Psychiatry, 125, 20–24.CrossRefGoogle ScholarPubMed
Carney, M. W. P. (1974). Choreiform movements after depot injections of flupenthixol. British Journal of Psychiatry, 125, 609.CrossRefGoogle ScholarPubMed
Carney, M. W. P., and Sheffield, B. F. (1973). The long-term maintenance treatment of schizophrenic out-patients with depot flupenthixol. Current Medical Research Opinion, 1, 423–426.CrossRefGoogle ScholarPubMed
Chien, C.-P. (1973). A new modality for treating schizophrenics in the community. In Community Management of the Schizophrenic in Chemical Remission, pp. 5–9. Edited by King, M. H.. Excerpta Medica: Amsterdam.Google Scholar
Chien, C.-P., DiMascio, A., and Cole, J. O. (1974). Antiparkinsonian agents and depot phenothiazine. American Journal of Psychiatry, 131, 86–90.CrossRefGoogle ScholarPubMed
Cole, J. O., Chien, C.-P., and Goldberg, H. (1973). Fluphenazine enanthate in community mental health in the United States. In The Future of Pharmacotherapy. New Drug Delivery Systems, pp. 33–35. Edited by Ayd, F. J. Jr.. International Drug Therapy Newsletter: Baltimore, Md.Google Scholar
Crawford, R., and Forrest, A. (1974). Controlled trial of depot fluphenazine in out-patient schizophrenics. British Journal of Psychiatry, 124, 385–391.CrossRefGoogle ScholarPubMed
Crumpton, N. (1967). Maintaining patients in the community. The rôle of drugs. British Journal of Geriatric Practice, 4, 186–192.Google Scholar
Crumpton, N. (1968). The role of drugs in maintaining patients in the community. In The Treatment of Mental Disorders in the Community, pp. 15–24. Edited by Daniel, G. R. and Freeman, H. L.. Baillière: London.Google Scholar
Davis, A. E., Dinitz, S., and Pasamanick, B. (1972). The prevention of hospitalization in schizophrenia. American Journal of Orthopsychiatry, 42, 375–388.CrossRefGoogle ScholarPubMed
De Alarcon, R., and Carney, M. W. P. (1969). Severe depressive mood changes following slow-release intramuscular fluphenazine injection. British Medical Journal, 3, 564–567.CrossRefGoogle ScholarPubMed
Degkwitz, R., Wenzel, W., Binsack, K. F., Herkert, H., and Luxemburger, O. (1966). Zum Probleme der terminalen extrapyramidalen Hyperkinesen an Hand von 1600 langfristig mit Neuroleptica Behandelten. Arzneimittelforschung 16, 276–9, quoted in Kennedy et al. British Journal of Psychiatry, 118, 509–518, 1971.Google Scholar
Ekdawi, M. Y., and Fowke, R. (1966). A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism. British Journal of Psychiatry, 112, 633–636.CrossRefGoogle ScholarPubMed
Engelhardt, D. M., and Freedman, N. (1969). Maintenance drug therapy: the schizophrenic patient in the community. In Social Psychiatry, vol. 1, pp. 256–282. Edited by Kiev, A.. Routledge: London.Google Scholar
Engelhardt, D. M., Freedman, N., Glick, B. S., Hankoff, L. D., and Mann, D. (1960). Prevention of psychiatric hospitalization with use of psychopharmacological agents. Journal of the American Medical Association, 173, 147–149. E. & R. Squibb (U.K.).CrossRefGoogle ScholarPubMed
Engelhardt, D. M., Rosen, B., Freedman, N., Mann, D., and Margolis, R. (1963). Phenothiazines in prevention of psychiatric hospitalization. II. Duration of treatment exposure. Journal of the American Medical Association, 186, 981–983.Google ScholarPubMed
Freeman, H. L. (1969). Long-Acting Phenothiazines in a Comprehensive Community Mental Health Service. Symposium on Long-Acting Phenothiazines, Dublin, 33–38. E. & R. Squibb (U.K.).Google Scholar
Freeman, H. (1973). Long-acting neuroleptics and their place in the community mental health service. In Community Management of the Schizophrenic in Chemical Remission, pp. 10–13. Edited by King, M. H.. Excerpta Medica: Amsterdam.Google Scholar
Fyrö, B., Wode-Helgodt, B., Borg, S., and Göran, S. (1974). The effect of chlorpromazine on homovanillic acid levels in cerebrospinal fluid of schizophrenic patients. Pharmacologia (Berl.), 35, 287–294.Google ScholarPubMed
Goldberg, E. M. (1971). Research in social work. In Portfolio for Health, pp. 99–108. Edited by McLachlan, G.. Oxford University Press: London.Google Scholar
Gottfries, C. G. (1971). Clinical trial of fluphenthixol decanoate as a depot neuroleptic. Nordisk Psykiatrisk Tidsskrift, 25, 296–303.CrossRefGoogle Scholar
Greenberg, L. M., and Roth, S. (1966). Differential effects of abrupt versus gradual withdrawal of chlorpromazine in hospitalized chronic schizophrenic patients. American Journal of Psychiatry, 123, 221–226.CrossRefGoogle ScholarPubMed
Grove, L., and Crammer, J. L. (1972). Benzhexol and side effects with long-acting fluphenazine therapy. British Medical Journal, 1, 276–279.CrossRefGoogle ScholarPubMed
Gunderson, J. G., IIIAutry, J. H., and Mosher, L. R., with Buchsbaum, S. (1974). Special report: Schizophrenia 1974. In Schizophrenia Bulletin, vol. 9, p. 46. National Institute of Mental Health: U.S. Dept. of Health, Education, and Welfare, Md.Google Scholar
Hirsch, S. R., Gaind, R., Rohde, P. D., Stevens, B. C., and Wing, J. K. (1973). Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. British Medical Journal, 1, 633–637.CrossRefGoogle ScholarPubMed
Hornykiewicz, O. (1966). Dopamine (3-hydroxytyramine) and brain function. Pharmacological Reviews, 18, 925–964.Google ScholarPubMed
Hunter, R., Earl, C. J., and Thornicroft, S. (1964). An apparently irreversible syndrome of abnormal movements following phenothiazine medication. Proceedings of the Royal Society of Medicine, 57, 758–762.CrossRefGoogle ScholarPubMed
Itil, T., and Keskiner, A. (1970). Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis. Diseases of the Nervous System, 31, Suppl., 37–42.Google ScholarPubMed
Kazamatsuri, H., Chien, C.-P., and Cole, J. O. (1972). Therapeutic approaches to tardive-dyskinesia. Archives of General Psychiatry, 27, 491–499.CrossRefGoogle ScholarPubMed
Kennedy, D. F., Hershon, H. I., and McGuire, R. J. (1971). Extrapyramidal disorders after prolonged phenothiazine therapy. British Journal of Psychiatry, 118, 509–518.CrossRefGoogle ScholarPubMed
Kety, S. S. (1967a). Current biochemical approaches to schizophrenia. New England Journal of Medicine, 276, 325–331.CrossRefGoogle ScholarPubMed
Kety, S. S. (1967b). The hypothetical relationships between amines and mental illness. In Amines and Schizophrenia, pp. 271–277. Edited by Himwich, H. E., Kety, S. S., and Smythies, J. R.. Pergamon: Oxford.CrossRefGoogle Scholar
Laduron, P. (1971). Pimozide (Orap): metabolism and interactions with cerebral amines. Journal of Clinical Trials, 8, Suppl. 2, 19–24.Google Scholar
Leff, J. P., and Wing, J. K. (1971). Trial of maintenance therapy in schizophrenia. British Medical Journal, 3, 599–604.CrossRefGoogle ScholarPubMed
Lowther, J. (1969). The effect of fluphenazine enanthate on chronic and relapsing schizophrenia. (Abstract.) British Journal of Psychiatry, 115, 691–692.CrossRefGoogle Scholar
McClelland, H. A., Blessed, G., Bhate, S., Ali, N., and Clarke, P. A. (1974). The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients. British Journal of Psychiatry, 124, 151–159.CrossRefGoogle ScholarPubMed
Martin, I. C. A. (1973). Some side effects of long-acting psychotropic drugs: potential and actual. In The Future of Pharmacotherapy. New Drug Delivery Systems, pp. 89–95. Edited by Ayd, F. J.. International Drug Therapy Newsletter: Baltimore, Md.Google Scholar
Mason, A. S., Forrest, I. S., Forrest, F. M., and Butler, H.. (1963). Adherence to maintenance therapy and rehospitalization. Diseases of the Nervous System, 24, 103–104.Google Scholar
Matthysse, S. (1973). Antipsychotic drug actions: a clue to the neuropathology of schizophrenia? Federation Proceedings, 32, 200–205.Google Scholar
Mattock, G. L., Wilson, D. L., and Hoffer, A. (1967). Catecholamine metabolism in schizophrenia. Nature, 213, 1189–1190.CrossRefGoogle Scholar
Miller, R. J., and Hiley, C. R. (1974). Anti-muscarinic properties of neuroleptics and drug-induced Parkinsonism. Nature, 248, 596–597.CrossRefGoogle ScholarPubMed
Mindham, R. H. S., Gaind, R., Anstee, B. H., and Rimmer, L. (1972). Compariso of anmantidine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism. Psychological Medicine, 2, 406–413.CrossRefGoogle Scholar
National Schizophrenia Fellowship (1973). Schizophrenia—the Family Burden. National Schizophrenia Fellowship: London.Google Scholar
National Schizophrenia Fellowship (1974). Living with Schizophrenia:—by the Relatives (1974) National Schizophrenia Fellowship: London.Google Scholar
Orlöv, P., Kasparian, G., DiMascio, A., and Cole, J. O. (1971). Withdrawal of antiparkinson drugs. Archives of General Psychiatry, 25, 410–412.CrossRefGoogle ScholarPubMed
Pasamanick, B., Scarpitti, F. R., and Dinitz, S. (1967). Schizophrenics in the Community. Appleton-Century-Crofts: New York.Google Scholar
Platt, R. (1968). The long-acting phenothiazines: a nurse's view. British Journal of Social Psychiatry, 2, 187–191.Google Scholar
Polvan, N. (1970). Fluphenazine hydrochloride and enanthate in the management of chronic psychosis. Diseases of the Nervous System, 31, Suppl., 48–49.Google ScholarPubMed
Pope, A. (1974). Problems of interpretation in the chemical pathology of schizophrenia. Journal of Psychiatric Research, 11, 265–272.CrossRefGoogle ScholarPubMed
Prien, R. F., and Klett, C. J. (1972). An appraisal of the long-term use of tranquilizing medication with hospitalized chronic schizophrenics: a review of the drug discontinuation literature. Schizophrenia Bulletin, No. 5, 64–73.CrossRefGoogle Scholar
Rackensperger, W., Gaupp, R., Mattke, D. J., Schwarz, D., and Stutte, K. H. (1974). Behandlung von akuten schizophrenen Psychosen mit Beta-Receptoren-Blockern. Archive für Psychiatrie und Nervenkrankheiten, 219, 29–36.CrossRefGoogle Scholar
Richmond, P. W. (1968). High-dosage fluphenazine. British Medical Journal, 2, 178.CrossRefGoogle ScholarPubMed
Shepherd, M., and Watt, D. C. (1975). Impact of Long-Term Neuroleptics on the Community: Advantages and Disadvantages. International Congress C.I.N.P., Paris. (In press.)Google Scholar
Simpson, G. M. (1970). Long-acting, antipsychotic agents and extrapyramidal side effects. Diseases of the Nervous System, 31, Suppl., 12–14.Google ScholarPubMed
Stein, L., and Wise, C. D. (1971). Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science, 171, 1032–1036.CrossRefGoogle Scholar
Stevens, B. C. (1972). Dependence of schizophrenic patients on elderly relatives. Psychological Medicine, 2, 17–32.CrossRefGoogle ScholarPubMed
Stevens, B. C. (1973). Role of fluphenazine decanoatei lessening the burden of chronic schizophrenics on the community. Psychological Medicine, 3, 141–158.CrossRefGoogle ScholarPubMed
Taylor, K. M. (1974). Displacement of bound 14C-fluphenazine by biogenic amines and antipsychotic drugs in homogenates of brain tissue. Nature, 252, 238–241.CrossRefGoogle ScholarPubMed
Trabucchi, M., Cheney, D., Racagni, G., and Costa, E. (1974). Involvement of brain cholinergic mechanisms in the action of chlorpromazine. Nature, 249, 664–666.CrossRefGoogle ScholarPubMed
Uhrbrand, L., and Faurbye, A. (1960). Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacologia, 1, 408–418.CrossRefGoogle Scholar
Vartanyan, M. E. (1969). Anxiety and the Stress Reaction in Different Forms of Schizophrenia, pp. 28–31. British Journal of Psychiatry, Special Publication No. 3.Google Scholar
Vogt, M. (1974). Behavioral effects of central catecholamines: concluding remarks. Journal of Psychiatric Research, 11, 183–184.CrossRefGoogle ScholarPubMed